Trinity Intangible Assets from 2010 to 2026
| TRIB Stock | USD 0.79 0.03 3.66% |
Intangible Assets | First Reported 1993-12-31 | Previous Quarter 53.7 M | Current Value 57.8 M | Quarterly Volatility 40.8 M |
Check Trinity Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Trinity Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.5 M, Total Revenue of 78.3 M or Gross Profit of 35 M, as well as many indicators such as Price To Sales Ratio of 1.4, Dividend Yield of 0.0019 or Days Sales Outstanding of 90.37. Trinity financial statements analysis is a perfect complement when working with Trinity Biotech Valuation or Volatility modules.
Trinity | Intangible Assets | Build AI portfolio with Trinity Stock |
Analyzing Trinity Biotech's Intangible Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Intangible Assets has evolved provides context for assessing Trinity Biotech's current valuation and future prospects.
Latest Trinity Biotech's Intangible Assets Growth Pattern
Below is the plot of the Intangible Assets of Trinity Biotech plc over the last few years. It is non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value. Trinity Biotech's Intangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Trinity Biotech's overall financial position and show how it may be relating to other accounts over time.
| Intangible Assets | 10 Years Trend |
|
Intangible Assets |
| Timeline |
Trinity Intangible Assets Regression Statistics
| Arithmetic Mean | 43,081,831 | |
| Geometric Mean | 32,937,563 | |
| Coefficient Of Variation | 64.39 | |
| Mean Deviation | 20,246,915 | |
| Median | 37,504,000 | |
| Standard Deviation | 27,739,070 | |
| Sample Variance | 769.5T | |
| Range | 107M | |
| R-Value | (0.24) | |
| Mean Square Error | 774.6T | |
| R-Squared | 0.06 | |
| Significance | 0.36 | |
| Slope | (1,302,139) | |
| Total Sum of Squares | 12311.3T |
Trinity Intangible Assets History
About Trinity Biotech Financial Statements
Trinity Biotech stakeholders use historical fundamental indicators, such as Trinity Biotech's Intangible Assets, to determine how well the company is positioned to perform in the future. Although Trinity Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Trinity Biotech's assets and liabilities are reflected in the revenues and expenses on Trinity Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Trinity Biotech plc. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Intangible Assets | 43.1 M | 42.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Trinity Biotech plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trinity Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trinity Biotech Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trinity Biotech Plc Stock:Check out the analysis of Trinity Biotech Correlation against competitors. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Trinity Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.77) | Earnings Share (1.80) | Revenue Per Share | Quarterly Revenue Growth 0.181 | Return On Assets |
Trinity Biotech plc's market price often diverges from its book value, the accounting figure shown on Trinity's balance sheet. Smart investors calculate Trinity Biotech's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Trinity Biotech's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.